Efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma.

Simple item page
dc.contributor.authorBachkheti, Nisha
dc.contributor.authorChalia, Dharamvir
dc.contributor.authorSehgal, Vijay Kumar
dc.contributor.authorWalia, Sachin
dc.date.accessioned2014-12-24T04:37:35Z
dc.date.available2014-12-24T04:37:35Z
dc.date.issued2014-11
dc.description.abstractBackground: This prospective, open, randomized, parallel-group, comparative study is to evaluate the efficacy and side-effect profile of travoprost (TRAV) 0.004% compared with tafluprost (TAF) 0.0015% in patients with primary open-angle glaucoma (POAG) over 12 weeks. A total of 80 patients of POAG selected and were randomized to either TRAV or TAF monotherapy administered once daily in the evening for 12 weeks. Methods: The study was conducted on 80 cases of POAG, in which patients were randomized to either TRAV or TAF monotherapy administered as 1 drop daily in the evening for 12 weeks. Intraocular pressure (IOP) was measured (8 am, 12 noon and 4 pm) at each visit, slit-lamp bio-microscopy was done and side effects noted. Results: The mean IOP reduction in TRAV group decreased from 27.58±2.30 to 19.03±2.326 thus resulting in fall of 8.55 (31.0%) and in TAF group it decreased from 27.38±2.676 to 20.58±2.827 resulting in fall of 6.8 mm Hg (24.8%) was significant (p<0.05). In both treatment groups, the most frequently reported adverse event at 12 weeks was red eye, noted in, 9 (22.5%) and 7 (17.5%) cases of TRAV and TAF groups respectively, though the difference was not statistically significant. Conclusion: TRAV 0.004% monotherapy produced lower diurnal IOP than TAF 0.0015% in patients with POAG and exhibited a similar safety profile.en_US
dc.identifier.citationBachkheti Nisha, Chalia Dharamvir, Sehgal Vijay Kumar, Walia Sachin. Efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma. International Journal of Basic & Clinical Pharmacology. 2014 Nov-Dec; 3(6): 958-963.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/154174
dc.language.isoenen_US
dc.source.urihttps://www.ijbcp.com/?mno=170491en_US
dc.subjectPrimary open-angle glaucomaen_US
dc.subjectIntraocular pressureen_US
dc.subjectTafluprosten_US
dc.subjectTravoprosten_US
dc.titleEfficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2014v3n6p958.pdf
Size:
513.52 KB
Format:
Adobe Portable Document Format
Description:
Research Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Basic & Clinical Pharmacology